Latest Ratios: P/E Ratio -4.3x · EV/EBITDA N/A · ROE -141.1%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.7B | $917M | $53M | $21M | $8M | $24M | — | — | — |
| Enterprise Value | $1.7B | $888M | $28M | $12M | $8M | $8M | — | — | — |
| P/E Ratio → | -4.27 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 31.56 | 8.55 | — | — | — | — |
| P/B Ratio | 37.51 | 30.36 | 7.16 | — | — | 1.46 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 18.39 | 8.28 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | 100.0% | — | — | — | — |
| Operating Margin | — | — | — | -3077.6% | -1898.2% | — | — | — | — |
| Net Profit Margin | — | — | — | -4525.0% | -1898.8% | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -141.1% | -141.1% | -2028.1% | — | -225.5% | -145.0% | — | — | — |
| ROA | -65.7% | -65.7% | -160.2% | -359.2% | -167.5% | -105.7% | -2249.3% | -9600.0% | -3862.1% |
| ROIC | — | — | — | — | — | -16223.5% | — | — | — |
| ROCE | -156.4% | -156.4% | -1527.6% | — | -223.2% | -128.5% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.10 | — | — | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.96 | -3.41 | — | — | -0.99 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -373.01 | -373.01 | -516.31 | -371.49 | -3008.67 | -14.95 | -8.28 | -14.58 | — |
Net cash position: cash ($29M) exceeds total debt ($117000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.59 | 2.59 | 1.28 | 0.76 | 0.81 | 8.75 | 0.07 | 0.02 | 0.02 |
| Quick Ratio | 2.59 | 2.59 | 1.28 | 0.76 | 0.81 | 8.75 | 0.07 | 0.02 | 0.02 |
| Cash Ratio | 2.18 | 2.18 | 1.08 | 0.55 | 0.14 | 7.88 | — | 0.02 | 0.02 |
| Asset Turnover | — | — | — | 0.05 | 0.34 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 2.1% | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 2.1% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $159M | $7M | $2M | $2M | $1M | $2M | $847146 | $794322 |
Binary Regulatory Funding Risk
According to current market data, UNCY trades at a price-to-book ratio of 37.51, which suggests that investors are assigning significant value to the company's intellectual property and regulatory pathway rather than its current tangible asset base, despite the absence of any meaningful revenue or earnings generation.
The elevated P/B multiple indicates that the market is pricing the firm as a high-stakes option on the successful commercialization of Renazorb. This valuation appears disconnected from traditional fundamental metrics, reflecting instead the binary nature of the company's clinical-stage pipeline and the potential for future dilution.
As reported in recent financial statements, UNCY's ROE has remained consistently negative, reaching -37.8% in 2026Q1, which highlights the ongoing destruction of shareholder capital as the firm prioritizes clinical trial progression and regulatory filings over the generation of any positive return on invested capital.
The persistent negative returns on capital are a structural feature of a pre-revenue biotech firm that must fund long-term R&D through equity issuance. Investors should monitor whether the company can transition toward a positive ROIC profile once the commercialization phase begins, though this remains highly speculative.
Based on the provided quarterly data, the company's current ratio of 2.40 as of 2026Q1 suggests a temporary ability to cover near-term obligations, yet this liquidity position is rapidly deteriorating as the firm burns through its cash reserves to fund the final stages of its regulatory strategy.
While the current ratio appears adequate on the surface, it masks the reality that the company lacks a self-sustaining revenue stream to replenish its cash balance. The reliance on external financing to maintain this liquidity level warrants further investigation into the timing and terms of future capital raises.
The most commonly misapplied metric for UNCY is the P/E ratio, which, at -4.27, provides no meaningful insight into the company's value because the firm is currently pre-revenue and lacks the operational scale required for traditional earnings-based valuation models to be relevant to the business.
Investors should instead focus on the probability-adjusted net present value of the Renazorb pipeline and the company's cash runway relative to its burn rate. Using P/E ratios for a clinical-stage biotech obscures the fundamental reality that the company's value is derived from regulatory milestones rather than current profitability.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying UNCY stock.
Unicycive Therapeutics, Inc.'s current P/E ratio is -4.3x. This places it at the 50th percentile of its historical range.
Unicycive Therapeutics, Inc.'s return on equity (ROE) is -141.1%. The historical average is -170.6%.
Based on historical data, Unicycive Therapeutics, Inc. is trading at a P/E of -4.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.